Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Johnson & Johnson

Schwab U.S. Dividend Equity ETF ($SCHD) and Vanguard High Dividend Yield Index ETF ($VYM) are two of the closely watched dividend exchange-traded f...

SCHD vs. VYM: Which Dividend ETF Can Make You More Money in 2026?

Lowe’s ($LOW), Amcor ($AMCR), and Johnson & Johnson ($JNJ) are the three dividend aristocrat stocks with a Strong Buy rating on Wall Street and pay...

3 Strong Buy Dividend Aristocrat Stocks, According to Top Analysts — June 16, 2026

Exchange-traded funds can be an attractive choice for investors seeking broad market exposure and reduced stock-specific risk. Interestingly, ETFs ...

Best ETFs to Invest In, According to AI Analyst, 6/12/2026

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aethlon Medical (AEMD), Johnson & Johnson (JNJ) an...

Analysts Offer Insights on Healthcare Companies: Aethlon Medical (AEMD), Johnson & Johnson (JNJ) and Phreesia (PHR)

Johnson & Johnson ( ($JNJ) ) has been popular among investors this week. Here is a recap of the key news on this stock. Johnson & Johnson investors...

Johnson & Johnson Rival Medline Rocked by FDA Crackdown

Investors often prefer exchange-traded funds (ETFs) for their diversification benefits and low cost. They can choose from a vast universe of ETFs b...

Best ETFs to Invest In, According to AI Analyst, 6/5/2026

In a report released today, Vamil Divan from Guggenheim maintained a Buy rating on Johnson & Johnson, with a price target of $266.00. According to ...

Johnson & Johnson (JNJ) Gets a Buy from Guggenheim

Medline’s ($MDLN) shares trimmed their Tuesday losses, rising over 1% during Wednesday’s pre-market session despite the manufacturing practice cont...

Medline Stock (MDLN) Rises despite FDA Controversy — Here’s Why

Medline’s ($MDLN) shares dropped about 7% on Tuesday afternoon after the U.S. health watchdog issued a warning letter to the company — a medical su...

Johnson & Johnson Rival Medline Stock (MDLN) Sinks on FDA Warning over Production Practices

Scotiabank analyst Louise Chen maintained a Buy rating on Johnson & Johnson today and set a price target of $265.00. Chen covers the Healthcare sec...

Scotiabank Sticks to Their Buy Rating for Johnson & Johnson (JNJ)

Investors are increasingly turning to exchange-traded funds (ETFs) for their flexibility, broad market access, diversification, and liquidity. Give...

Best ETFs to Invest In, According to AI Analyst, 5/29/2026

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Staar Surgical (STAA), Johnson & Johnson (JNJ) and A...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Exchange-traded funds (ETFs) continue to be a popular investment choice for investors, given their diversification benefits, low costs, liquidity, ...

Best ETFs to Invest In, According to AI Analyst, 5/28/2026

Stocks ended the week on a firm note, with the Dow Jones closing at a new high as bond yields eased and tech shares helped lift the broader market....

Market Cap	$459.32B	P/E Ratio	19.74
52W High	$251.71	52W Low	$149.04
Div Yield	536.0%	Payout Ratio	59.5%
EPS Growth 3Y	17.7%	52W Position	77.3%
Overall Score	57	Value Score	70
Quality Score	39	Technical Score	63

EPS Current Est	$11.57	EPS Next Est	$12.6
EPS Growth Est	+8.9%	DPS Growth 3Y	0.0%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	JNJ	$228.39	-2.48%	18.99M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	JNJ	$228.39	-2.5%	18.99M
3
4
5
6

JNJ

JNJ

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Johnson & Johnson Data in Excel

Get Johnson & Johnson Data in Excel